Insomnia Disorder
Conditions
Keywords
Compound Ciwujia Granules, multicenter, randomized controlled trial, insomnia
Brief summary
The goal of this multicenter, double-blind, double-dummy, randomized controlled trial was to examine the efficacy and safety of Compound Ciwujia Granules in the treatment of chronic insomnia. A total of 1200 participants with chronic insomnia were randomly assigned to receive one of the three treatment for 4 consecutive weeks: Compound Ciwujia Granules + placebo of estazolam, estazolam + placebo of estazolam + placebo of Compound Ciwujia Granules, or Compound Ciwujia Granules + estazolam + placebo of estazolam. Outcomes were assessed at 2 weeks, 4 weeks, 8 weeks, and 12 weeks. The main questions it aims to answer are: 1. Are there any significant differences between groups regarding changes in Pittsburgh Sleep Quality Index (PSQI) score, Insomnia Severity Index (ISI) score, subjective sleep latency, sedative and hypnotics use, improvement in sleep maintenance, Hamilton Depression Scale (HAMD-17) score, Hamilton Anxiety Scale (HAMA-14) score, Flinders Fatigue Scale (FFS) score, and constitution classification/insomnia pattern score of traditional Chinese medicine after 4 weeks' treatment, and follow-up at 8 weeks and 12 weeks. 2. Is the Compound Ciwujia Granules a safe method for chronic insomnia treatment in adults?
Detailed description
The investigators aimed to examine the efficacy and safety of Compound Ciwujia Granules in the treatment of chronic insomnia in a multicenter, double-blind, double-dummy, randomized controlled clinical trial. Eligible participants were adults aged 40-75 years who had insomnia disorder (according to the Diagnostic and Statistical Manual of Mental Disorders, fifth edition \[DSM5\]) or self-reported history of disturbed sleep, diagnosis of deficiency of the heart and the spleen pattern or Qi deficiency of the heart and gallbladder pattern according to the guidelines for Integrated Traditional Chinese and Western Medicine Treatment of Insomnia Disorders 2023, baseline Pittsburgh Sleep Quality Index (PSQI) score ≥ 8. The exclusion criteria were (1) self-reported allergy symptoms to any of the ingredients; (2) serious physical sickness; (3) a history of suicidal ideation or attempt, acute or chronic psychiatric condition not controlled by therapy; (4) baseline HAMD-17 score ≥17 or HAMA-14 score ≥14;(5) pregnant women; (6) history of drugs or alcohol abuse/dependence; (7) presence of other sleep disorders including sleep apnoea, restless legs syndrome; (8) night, morning or rotating shift work; (9) participation in concurrent clinical trials. The primary outcome was the change in Pittsburgh Sleep Quality Index (PSQI) score after 4 weeks' treatment. The secondary outcomes were changes in Insomnia Severity Index (ISI) score, subjective sleep latency, sedative and hypnotics use, improvement in sleep maintenance, Hamilton Depression Scale (HAMD-17) score, Hamilton Anxiety Scale (HAMA-14) score, Flinders Fatigue Scale (FFS) score, and constitution classification/insomnia pattern score of traditional Chinese medicine, as well as the occurrence of adverse events after 4 weeks' treatment, and follow-up at 8 weeks and 12 weeks. The main questions it aims to answer are: 1. Are there any significant differences between groups regarding changes in Pittsburgh Sleep Quality Index (PSQI) score, Insomnia Severity Index (ISI) score, subjective sleep latency, sedative and hypnotics usage, improvement in sleep maintenance, Hamilton Depression Scale (HAMD-17) score, Hamilton Anxiety Scale (HAMA-14) score, Flinders Fatigue Scale (FFS) score, and constitution classification/insomnia pattern score of traditional Chinese medicine after 4 weeks' treatment, and follow-up at 8 weeks and 12 weeks. 2. Is the Compound Ciwujia Granules a safe method for chronic insomnia treatment in adults?
Interventions
DRUGCompound Ciwujia Granules group
Compound Ciwujia Granules for 4 consecutive weeks combined with placebo of estazolam for 4 consecutive weeks
DRUGEstazolam
estazolam for 2 consecutive weeks + placebo of estazolam for 2 consecutive weeks combined with placebo of Compound Ciwujia Granules for 4 consecutive weeks
DRUGCompound Ciwujia Granules and estazolam
Compound Ciwujia Granules for 4 consecutive weeks combined with estazolam for 2 consecutive weeks+ placebo of estazolam for 2 consecutive weeks
Sponsors
Hui Zhu
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
40 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Eligible participants were adults aged 40-75 years who had insomnia disorder (according to the Diagnostic and Statistical Manual of Mental Disorders, fifth edition \[DSM5\]); 2. self-reported history of disturbed sleep (i.e, all the following: ≥30 min to fall asleep, ≥30 min awake during sleep time, and self-reported total sleep time of ≤6·5 h) on at least three nights per week for at least 3 months before screening;(3) diagnosis of deficiency of the heart and the spleen pattern or Qi deficiency of the heart and gallbladder pattern according to the guidelines for Integrated Traditional Chinese and Western Medicine Treatment of Insomnia Disorders 2023; (4) baseline Pittsburgh Sleep Quality Index (PSQI) score ≥ 8.
Exclusion criteria
1. self-reported allergy symptoms to any of the ingredients; 2. serious physical sickness; 3. a history of suicidal ideation or attempt, acute or chronic psychiatric condition not controlled by therapy; 4. baseline HAMD-17 score ≥17 or HAMA-14 score ≥14; 5. pregnant women; 6. history of drugs or alcohol abuse/dependence; 7. presence of other sleep disorders including sleep apnoea, restless legs syndrome; 8. night, morning or rotating shift work; 9. participation in concurrent clinical trials.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pittsburgh Sleep Quality Index (PSQI) score | From enrollment to the end of treatment at 4 weeks, and follow-up at 8 weeks and 12 weeks. | PSQI score, 0-21, and higher scores mean a poorer sleep quality. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Hamilton Depression Scale (HAMD-17) score | From enrollment to the end of treatment at 4 weeks, and follow-up at 8 weeks and 12 weeks | HAMD-17 score, 0-55, and higher scores mean more severe depression. |
| Insomnia Severity Index (ISI) score | From enrollment to the end of treatment at 4 weeks, and follow-up at 8 weeks and 12 weeks. | ISI score, 0-28, and higher scores mean a worse sleep problem |
| Hamilton Anxiety Scale (HAMA-14) score | From enrollment to the end of treatment at 4 weeks, and follow-up at 8 weeks and 12 weeks. | HAMA-14 score, 0-56, and higher scores mean more severe anxiety |
| Flinders Fatigue Scale (FFS) score | From enrollment to the end of treatment at 4 weeks, and follow-up at 8 weeks and 12 weeks | FFS score, 0-31, and higher scores mean more severe fatigue |
| Occurrence of adverse events | From enrollment to the end of treatment at 4 weeks, and follow-up at 8 weeks and 12 weeks. | — |
Other
| Measure | Time frame | Description |
|---|---|---|
| Insomnia pattern score of traditional Chinese medicine | From enrollment to the end of treatment at 4 weeks | Insomnia pattern score of traditional Chinese medicine, 0-41, and higher scores mean a worse sleep problem |
| Use of sedatives and hypnotics | From enrollment to the end of treatment at 4 weeks, and follow-up at 8 weeks, and 12 weeks. | If it exists, provide information on the use of sedatives or hypnotics (e.g. drug names, dose, and duration) |
| Constitution classification of traditional Chinese medicine | From enrollment to the end of treatment at 4 weeks | Constitution classification score of traditional Chinese medicine, 0-100, and higher scores mean more likely to have the specified constitution classification. |
| Sleep diary | From enrollment to the end of treatment at 4 weeks | Providing daily information on subjective sleep onset latency, subjective total sleep time, subjective sleep quality, subjective wake after sleep onset, and subjective number of awakenings. |
Contacts
Primary ContactGang Chen, PhD
Outcome results
None listed